Minophagen acquires Japanese rights to Eisai's bexarotene
This article was originally published in Scrip
Executive Summary
Eisai has sublicensed exclusive Japanese development and commercialisation rights to its oncology product bexarotene to Minophagen Pharmaceutical, retaining an option to co-promote the retinoid molecule in this market as part of the deal.